Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
Infection & Chemotherapy 2020³â 52±Ç 3È£ p.396 ~ p.402
È«°æ¼ö(Hong Kyung-Soo) - Yeungnam University College of Medicine Department of Internal Medicine
ÀåÁ¾°É(Jang Jong-Geol) - Yeungnam University College of Medicine Department of Internal Medicine
ÇãÁö¾È(Hur Ji-An) - Yeungnam University College of Medicine Department of Internal Medicine
ÀÌÁ¾È£(Lee Jong-Ho) - Yeungnam University College of Medicine Department of Laboratory Medicine
±èÈ«³²(Kim Hong-Nam) - Korea Institute of Science and Technology Brain Science Institute Center for BioMicrosystems
ÀÌ¿øÈ(Lee Won-Hwa) - Korea Research Institute of Bioscience and Biotechnology Aging Research Center
¾ÈÁØÈ«(Ahn June-Hong) - Yeungnam University College of Medicine Department of Internal Medicine
Abstract
There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.
Å°¿öµå
Early, Hydroxychloroquine, Coronavirus disease 2019, Eradication
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Early HCQ administration group had a higher initial NEWS (2.5 (IQR 0.75 - 5.0) vs. 1.0 (IQR 0 - 2.0), P = 0.002), and many had progressed toward ARDS (21.4% vs. 4.2%, P = 0.021) and septic shock (9.5% vs. 0.0%, P = 0.044).